Organon Eei (Europe East & Israel)

Organon Eei (Europe East & Israel) company information, Employees & Contact Information

At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women’s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.

Company Details

Employees
20
Founded
-
Address
Národní 135, Prague 1,prague 11000,czech Republic
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Prague 1, Prague
Looking for a particular Organon Eei (Europe East & Israel) employee's phone or email?

Organon Eei (Europe East & Israel) Questions

News

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 - Business Wire

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 Business Wire

Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune

Organon (OGN): Company Profile, Stock Price, News, Rankings Fortune

UNFPA Thailand Joins Organon Thailand to Empower Women to Shape Their Own Future - Khaosod English

UNFPA Thailand Joins Organon Thailand to Empower Women to Shape Their Own Future Khaosod English

Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued - Stock Titan

Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued Stock Titan

Organon Reports Results for the First Quarter Ended March 31, 2025 - Business Wire

Organon Reports Results for the First Quarter Ended March 31, 2025 Business Wire

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - FinancialContent

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 FinancialContent

Organon calls for greater awareness on Cardiovascular Disease Prevention for women - Inquirer.net

Organon calls for greater awareness on Cardiovascular Disease Prevention for women Inquirer.net

(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire

(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Business Wire

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Yahoo Finance

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors Yahoo Finance

Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz

Organon Appoints Company Executive Joseph Morrissey as Interim CEO citybiz

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - GlobeNewswire

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% GlobeNewswire

UNFPA, Organon and MIT Solve announce the 14 winners of the 4HerPower Challenge - United Nations Population Fund

UNFPA, Organon and MIT Solve announce the 14 winners of the 4HerPower Challenge United Nations Population Fund

Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data - Center for Biosimilars

Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data Center for Biosimilars

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) - 复宏汉霖

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) 复宏汉霖

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Yahoo Finance

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Yahoo Finance

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA - Business Wire

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA Business Wire

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection - Business Wire

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection Business Wire

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator - Business Wire

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator Business Wire

Organon Launches as New Women’s Health Company - Business Wire

Organon Launches as New Women’s Health Company Business Wire

Making Organon’s operating model fit for the future. - Accenture

Making Organon’s operating model fit for the future. Accenture

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist - Business Wire

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist Business Wire

Organon: It's Darkest Before The Dawn (NYSE:OGN) - Seeking Alpha

Organon: It's Darkest Before The Dawn (NYSE:OGN) Seeking Alpha

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia - Business Wire

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia Business Wire

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024 - The AI Journal

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024 The AI Journal

Organon Juan Camilo Arjona Ferreira, M.D., as CMO and Charlotte Owens, MD, FACOG, as Head of Medical Affairs and Outcomes Research - citybiz

Organon Juan Camilo Arjona Ferreira, M.D., as CMO and Charlotte Owens, MD, FACOG, as Head of Medical Affairs and Outcomes Research citybiz

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy - Business Wire

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy Business Wire

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield (OGN) - Seeking Alpha

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield (OGN) Seeking Alpha

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued (OGN) - Seeking Alpha

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued (OGN) Seeking Alpha

Organon to Acquire Forendo Pharma - Business Wire

Organon to Acquire Forendo Pharma Business Wire

FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA - Business Wire

FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA Business Wire

Organon Announces Pricing of $1.0 Billion Senior Notes Offering - The AI Journal

Organon Announces Pricing of $1.0 Billion Senior Notes Offering The AI Journal

ADDING MULTIMEDIA Organon Launches as New Global Women’s Health Company - Business Wire

ADDING MULTIMEDIA Organon Launches as New Global Women’s Health Company Business Wire

Organon Acquires Forendo Pharma - citybiz

Organon Acquires Forendo Pharma citybiz

FDA Extends Organon's VTAMA Review by 3 Months; $125M Revenue Target Still on Track - Stock Titan

FDA Extends Organon's VTAMA Review by 3 Months; $125M Revenue Target Still on Track Stock Titan

System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology - Business Wire

System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology Business Wire

PLAS, Organon spotlight heart health, urge early action against high cholesterol - Inquirer.net

PLAS, Organon spotlight heart health, urge early action against high cholesterol Inquirer.net

Organon Canada Announces the Availability of NDUVRA® (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults - PR Newswire Canada

Organon Canada Announces the Availability of NDUVRA® (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults PR Newswire Canada

Organon underscores the importance of contraceptive education on World Contraception Day - Inquirer.net

Organon underscores the importance of contraceptive education on World Contraception Day Inquirer.net

Organon and ObsEva Enter Global License Agreement to - GlobeNewswire

Organon and ObsEva Enter Global License Agreement to GlobeNewswire

Innovating for women’s health: Addressing PPH with the JADA® System - Inquirer.net

Innovating for women’s health: Addressing PPH with the JADA® System Inquirer.net

Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer - PR Newswire Canada

Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer PR Newswire Canada

Organon announces commitment to accelerating advancements in women's health at EXPO 2020 - PR Newswire UK

Organon announces commitment to accelerating advancements in women's health at EXPO 2020 PR Newswire UK

Organon Canada Launches as New Women's Health Company - PR Newswire Canada

Organon Canada Launches as New Women's Health Company PR Newswire Canada

Organon Acquires Contraceptive Products, Marvelon ® and Mercilon ® , in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam - NTB Kommunikasjon

Organon Acquires Contraceptive Products, Marvelon ® and Mercilon ® , in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam NTB Kommunikasjon

Top Organon Eei (Europe East & Israel) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant